Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy
Open Access
- 9 February 2023
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-17
Abstract
Background: Transporter associated with antigen processing 1 (TAP1) is a molecule involved in processing and presentation of major histocompatibility complex class I restricted antigens, including tumor-associated antigens. TAP1 participates in tumor immunity, and is aberrantly expressed in multiple cancer types; Methods: Transcriptome profiles were obtained from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Genetic alterations, protein distribution, and interaction information for TAP1 were downloaded from cBioPortal, Human Protein Atlas and Compartmentalized Protein–Protein Interaction, respectively. Single-cell analyses of TAP1 across cancers were conducted via the Tumor Immune Single-cell Hub website. Gene set enrichment analysis was employed to investigate TAP1-associated functional mechanisms and processes. Immune cell infiltration was explored using Tumor Immune Estimation Resource 2.0. Pan-cancer correlations between TAP1 expression and immunotherapy biomarkers were explored using the Spearman’s correlation test. Associations with immunotherapy responses were also investigated using clinicopathological and prognostic information from cohorts of patients with cancer receiving immune checkpoint inhibitors. Results: TAP1 expression was elevated in most cancer types and exhibited distinct prognostic value. Immune cells expressed more TAP1 than malignant cells within most tumors. TAP1 expression was significantly correlated with immune-related pathways, T-lymphocyte infiltration, and immunotherapeutic biomarkers. Clinical cohort validation revealed a significant correlation with immune therapeutic effects and verified the prognostic role of TAP1 in immunotherapy. Western blot assay indicated that TAP1 is upregulated in glioblastoma compared with adjacent normal brain tissues. Conclusion: TAP1 is a robust tumor prognostic biomarker and a novel predictor of clinical prognosis and immunotherapeutic responses in various cancer types.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81860448, 82002660, 82172989)
This publication has 46 references indexed in Scilit:
- limma powers differential expression analyses for RNA-sequencing and microarray studiesNucleic Acids Research, 2015
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Functions of the proteasome: from protein degradation and immune surveillance to cancer therapyBiochemical Society Transactions, 2007
- Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancerInternational Journal of Cancer, 2004
- The ABCs of Immunology: Structure and Function of TAP, the Transporter Associated with Antigen ProcessingPhysiology, 2004
- Interferon Induction of TAP1Circulation Research, 1998
- Interferon-γ Rapidly Increases Peptide Transporter (TAP) Subunit Expression and Peptide Transport Capacity in Endothelial CellsJournal of Biological Chemistry, 1997
- Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transportersNature, 1990
- Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium.Proceedings of the National Academy of Sciences, 1990
- α-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequencesNature, 1985